Abstract:1. Various factors, including genetic polymorphisms, drug-drug interactions, and patient characteristics influence the blood concentrations of tacrolimus in renal transplant patients. In the present study, we established a population pharmacokinetic model to explore the effect of combined use of Wuzhi capsules/echinocandins and the patients' biochemical parameters such as haematocrit on blood concentrations and target doses of tacrolimus in renal transplant patients with different CYP3A5 genotypes. The aim of the study was to propose an individualised tacrolimus administration regimen for early renal transplant recipients. 2. In this retrospective cohort study, we included 240 renal transplant recipients within 21 days of surgery (174 males and 66 females, mean age 39.4 years), who received tacrolimus alone (n = 54), in combination with Wuzhi capsules (99) or caspofungin (57) or micafungin (30). We collected demographic characteristics, clinical indicators, CYP3A5 genotypes, and 1950 steady-state concentrations of tacrolimus and included them in population pharmacokinetic model. An additional 110 renal transplant recipients and 625 steady-state concentrations of tacrolimus were included for external validation of the model. The population pharmacokinetic model was established and Monte Carlo was used to simulate probabilities for achieving the target concentration for individual tacrolimus administration. 3. A two-compartment model of first-order absorption and elimination was developed to describe the population pharmacokinetics of tacrolimus. CYP3A5 genotypes and co-administration of Wuzhi capsules, as well as time after renal transplantation and haematocrit, were important factors affecting the clearance of tacrolimus. We found no obvious change in trend in the scatter plot of tacrolimus clearance rate vs. haematocrit. The Monte Carlo simulation indicated the following recommended doses of tacrolimus alone: 0.14 mg.kg(-1).d(-1) for genotype CYP3A5*1*1, 0.12 mg.kg(-1).d(-1) for CYP3A5*1*3, and 0.10 mg.kg(-1).d(-1) for CYP3A5*3*3. For patients receiving the combination with Wuzhi capsules, the recommended doses of tacrolimus were 0.10 mg.kg(-1).d(-1) for CYP3A5*1*1, 0.08 mg.kg(-1).d(-1) for CYP3A5*1*3, and 0.06 mg.kg(-1).d(-1) for CYP3A5*3*3 genotypes. Caspofungin or micafungin had no effect on the clearance of tacrolimus in renal transplant recipients. 4. The population pharmacokinetics of tacrolimus in renal transplant patients was evaluated and the individual administration regimen of tacrolimus was simulated. For early kidney transplant recipients receiving tacrolimus treatment, not only body weight, but also CYP3A5 genotypes and drugs used in combination should be considered when determining the target dose of tacrolimus.

Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule

Initial Dosage Optimization of Tacrolimus in Chinese Pediatric Patients Undergoing Kidney Transplantation Based on Population Pharmacokinetics and Pharmacogenetics

Initial Dose Optimization of Tacrolimus for Children with Systemic Lupus Erythematosus Based on the CYP3A5 Polymorphism and Coadministration with Wuzhi Capsule.

Population Pharmacokinetics and Pharmacogenomics of Tacrolimus in Chinese Children Receiving a Liver Transplant: Initial Dose Recommendation

The Pharmacokinetic Study of Tacrolimus and Wuzhi Capsule in Chinese Liver Transplant Patients

Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome

Population Pharmacokinetics Model and Initial Dose Optimization of Tacrolimus in Children and Adolescents with Lupus Nephritis Based on Real-World Data

Population Pharmacokinetics and Dosage Optimization of Tacrolimus in Pediatric Patients with Nephrotic Syndrome

Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients

Population Pharmacokinetics and Dosage Optimisation of Tacrolimus Coadministration with Wuzhi Capsule in Adult Liver Transplant Patients

Effect of Drug Combination on Tacrolimus Target Dose in Renal Transplant Patients with Different CYP3A5 Genotypes

Optimizing the initial tacrolimus dosage in Chinese children with lung transplantation within normal hematocrit levels

Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome

Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients

Dosing Strategy of Tacrolimus when Co-Administered with Wuzhi Tablet in Renal Transplant Recipients.

Population Pharmacokinetics and Initial Dose Optimization of Tacrolimus in Children with Severe Combined Immunodeficiency Undergoing Hematopoietic Stem Cell Transplantation

Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients

Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients

Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome

Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach

Tacrolimus Starting Dose Prediction Based on Genetic Polymorphisms and Clinical Factors in Chinese Renal Transplant Recipients.